Compare · DFTX vs TLRY
DFTX vs TLRY
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Tilray Brands Inc. (TLRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and TLRY operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $3.95B, about 7.3x TLRY ($537.2M).
- Over the past year, DFTX is up 405.9% and TLRY is up 20.2% - DFTX leads by 385.6 points.
- DFTX has been more active in the news (21 items in the past 4 weeks vs 15 for TLRY).
- TLRY has more recent analyst coverage (14 ratings vs 5 for DFTX).
- Company
- Definium Therapeutics Inc.
- Tilray Brands Inc.
- Price
- $36.17-1.39%
- $4.61+0.66%
- Market cap
- $3.95B
- $537.2M
- 1M return
- +59.62%
- -15.57%
- 1Y return
- +405.87%
- +20.24%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 21
- 15
- Recent ratings
- 5
- 14
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Latest DFTX
- Needham reiterated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics, Inc. Announces Proposed Public Offering
- SEC Form 424B5 filed by Definium Therapeutics Inc.
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 42% to 212,500 units (SEC Form 4)
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 54% to 177,500 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Latest TLRY
- BrewDog Bars Draw Record Fan Turnout as Global Tournament Fever Drives Double-Digit Growth
- Breckenridge Distillery Releases Limited Single Barrel Bourbon Collection
- Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean Energy
- BrewDog Turns Up Father's Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat Free
- Breckenridge Distillery Celebrates America's 250th Anniversary with the Launch of Patriotic Reserve Bourbon Whiskey
- BrewDog USA Brings Summer Soccer to Life with Watch Parties and Fan Events in Las Vegas and Across Ohio
- Breckenridge Brewery Launches a Colorado-Wide Soccer Celebration with Fan-First Activations
- 10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration
- Shock Top Kicks Off the World's Biggest Summer of Soccer with Shocking Upsets
- BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team's Return